Heterogeneity of IPF exacerbations
- PMID: 34973212
- DOI: 10.1016/S2213-2600(21)00459-8
Heterogeneity of IPF exacerbations
Conflict of interest statement
SR reports grants and non-financial support from Oxford Respiratory National Institute for Health Research Biomedical Research Centre during the conduct of the study, and non-financial support from AstraZeneca and personal fees from the Australian Government Research Training Program outside the submitted work. MB reports grants from AstraZeneca; personal fees from AstraZeneca, Chiesi, and GlaxoSmithKline; and other support from Albus Health, ProAxsis, outside the submitted work.
Comment on
-
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir Med. 2022 Jan;10(1):26-34. doi: 10.1016/S2213-2600(21)00354-4. Epub 2021 Sep 7. Lancet Respir Med. 2022. PMID: 34506761 Clinical Trial.
-
Authors' reply.Lancet Respir Med. 2022 Jan;10(1):e4. doi: 10.1016/S2213-2600(21)00493-8. Lancet Respir Med. 2022. PMID: 34973213 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources